EUVIMEDEUVIMED entdecken
Crossref

Lack of effectiveness and seizure worsening with cenobamate in pediatric patients with Dravet syndrome

Rita Cagigal, Celia Romero-Del-Rincon, Ana Fernandez-Perrone, Raquel Cruz, Rikke S Møller iD, Angel Aledo-Serrano iD

Epilepsia · 2025-06 · 66 (6)

DOI: 10.1111/epi.18426 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, online erschienen am 28.04.2025. Verfasst von Rita Cagigal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Unit, Clinical Neuroscience Institute, Vithas Madrid University Hospitals, Madrid, Spain. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Anticonvulsants, Carbamates, Chlorophenols. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy primarily caused by loss‐of‐function (LoF) variants in the SCN1A gene. Despite advancements in precision medicine, seizure control remains challenging. Cenobamate, a novel antiseizure medication, has shown positive results in a small case series of adults with DS, but its efficacy in children is unclear. This retrospective and single‐center study analyzed the therapeutic response to cenobamate in six pediatric patients (median age = 8.5 years) with DS and SCN1A LoF variants. Patients were treated with cenobamate for a median follow‐up of 7 months. Baseline seizure frequency was assessed over 3 months prior to treatment initiation. Response was defined as a ≥50% reduction in seizure frequency and worsening as a ≥25% increase compared to baseline. No patient met the responder criteria. Three patients experienced seizure worsening, including one patient who started presenting status epilepticus after a long status epilepticus‐free period, and the remaining three showed no improvement. Adverse effects included sleepiness, restlessness, and loss of appetite, and cenobamate was discontinued in all patients due to lack of effectiveness or seizure worsening. Our findings suggest that cenobamate lacks effectiveness in pediatric DS and may exacerbate seizures in some cases. These results highlight the need for age‐specific approaches in treatment decisions for genetic epilepsies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicAnticonvulsantsCarbamatesChlorophenolsSeizuresHumansMaleChildFemaleRetrospective StudiesNAV1.1 Voltage-Gated Sodium ChannelChild, PreschoolAdolescentTreatment OutcomeTetrazoles

Stichwörter der Autor:innen

SCN1ADravet syndromeage‐specific medicinecenobamateepileptic encephalopathy

Substanzen

AnticonvulsantsCarbamatesCenobamateNAV1.1 Voltage-Gated Sodium ChannelChlorophenolsSCN1A protein, humanTetrazoles

Autor:innen und Institutionen

  • Epilepsy Unit, Clinical Neuroscience Institute, Vithas Madrid University Hospitals, Madrid, Spain.
  • Neurology Department, Unidade de Saúde Local de Gaia-Espinho, Vila Nova de Gaia, Portugal.
  • Department of Epilepsy, Genetics, and Personalized Medicine, Danish Epilepsy Center (EpiCARE member), Dianalund, Denmark.
  • Department of Regional Health Research, University of Southern Denmark, Odense, Denmark.

ORCID-Profile: Rikke S Møller, Angel Aledo-Serrano

Zitieren

APA

Cagigal, R., Romero-Del-Rincon, C., Fernandez-Perrone, A., Cruz, R., Møller, R. S., & Aledo-Serrano, A. (2025). Lack of effectiveness and seizure worsening with cenobamate in pediatric patients with Dravet syndrome. Epilepsia, 66(6). https://doi.org/10.1111/epi.18426

Vancouver

Cagigal R, Romero-Del-Rincon C, Fernandez-Perrone A, Cruz R, Møller RS, Aledo-Serrano A. Lack of effectiveness and seizure worsening with cenobamate in pediatric patients with Dravet syndrome. Epilepsia. 2025;66(6). doi:10.1111/epi.18426

BibTeX
@article{Cagigal2025,
  author = {Cagigal, Rita and Romero-Del-Rincon, Celia and Fernandez-Perrone, Ana and Cruz, Raquel and Møller, Rikke S and Aledo-Serrano, Angel},
  title = {Lack of effectiveness and seizure worsening with cenobamate in pediatric patients with Dravet syndrome},
  journal = {Epilepsia},
  year = {2025},
  volume = {66},
  number = {6},
  doi = {10.1111/epi.18426}
}
Kostenlos starten →